Table 3.
ARV Used in the First and Second Years of Follow-up Relative to Development of Incident Hypercholesterolemia
| Time Period Relative to Development of Hypercholesterolemia | |||||
|---|---|---|---|---|---|
| ARV Class | At Development of High Cholesterol | Within first Year a N= 240 | N (%) | Within second year b N=213 | N (%) |
| PI | On PI | Remained on PI | 221 (92.1) | Remained on PI | 191 (90.1) |
| Discontinued all PI | 4 (1.7) | Discontinued all PI | 10 (4.7) | ||
| Not on PI | Not on PI | 13 (5.4) | Not on PI | 8 (3.8) | |
| Started PI | 2 (0.8) | Started PI | 3 (1.4) | ||
| NNRTI | On NNRTI | Remained on NNRTI | 85 (35.4) | Remained on NNRTI | 69 (32.4) |
| Discontinued NNRTI | 12 (5.0) | Discontinued NNRTI | 18 (8.4) | ||
| Not on NNRTI | Not on NNRTI | 140 (58.3) | Not on NNRTI | 120 (56.3) | |
| Started NNRTI | 3 (1.2) | Started NNRTI | 6 (2.8) | ||
| NRTI | On NRTI | Remained on NRTI | 230 (95.8) | Remained on NRTI | 201 (94.4) |
| Discontinued NRTI | 2 (0.8) | Discontinued NRTI | 7 (3.3) | ||
| Not on NRTI | Not on NRTI | 7 (2.9) | Not on NRTI | 4 (1.9) | |
| Started NRTI | 1 (0.4) | Started NRTI | 1 (0.5) | ||
|
| |||||
| Specific ARVc | Not on ATV | Started ATV | 4/236 | Started ATV | 6/213 |
| On Boosted PI | Switched to non-boosted | 2/119 | Switched to non-boosted | 1/104 | |
| Switched to no PI | 4/119 | Switched to no PI | 5/104 | ||
| On Specific PI | Discontinued | Discontinued | |||
| Ritonavir or LPV/r | 6/153 | Ritonavir or LPV/r | 11/136 | ||
| Amprenavir | 2/10 | Amprenavir | 4/7 | ||
| Nelfinavir | 6/72 | Nelfinavir | 11/66 | ||
| Indinavir | 0/11 | Indinavir | 1/10 | ||
| Saquinavir | 1/14 | Saquinavir | 3/13 | ||
| On EFV | Stopped EFV | 10/53 | Stopped EFV | 13/48 | |
| Switched from EFV to NVP | 1/53 | Switched from EFV to NVP | 2/48 | ||
| On EFV + PI | On PI, Dropped EFV | 6/48 | On PI, Dropped EFV | 8/44 | |
| On d4T | Stopped d4T, started TDF or ABC | 3/137 | Stopped d4T, started TDF or ABC | 5/123 | |
| On ZDV | Stopped ZDV, started TDF or ABC | 0/25 | Stopped ZDV, started TDF or ABC | 1/22 | |
| Not on TDF | Started TDF | 5/227 | Started TDF | 18/195 | |
a
240 children had incident hypercholesterolemia
b
27 of 240 had follow-up for less than 365 days after hypercholesterolemia and are not counted in the second year
c
Switches presented are those associated with improvements in cholesterol cited in the literature d Protease inhibitor (PI), Nucleoside reverse transcriptase inhibitor (NRTI), Non-nucleoside reverse transcriptase inhibitor (NNRTI), tenofovir (TDF), zidovudine (ZDV), abacavir (ABC), atazanavir (ATV), efavirenz (EFV), nevirapine (NVP), lopinavir/ritonavir (LPV/r)